Have we reached the limits for the treatment of diabetic nephropathy?

Bibliography

• Stevens LA, Levey AS. Current status and future perspectives for CKD testing. Am J kidney Dis 2009;53(3 Suppl 3):S17-26
   PubMed Web of Science ®Google Scholar
• Vassalotti JA, Stevens LA, Levey AS. Testing for chronic kidney disease: a position statement from the National Kidney Foundation. Am J kidney Dis 2007;50(2):169-80
   PubMed Web of Science ®Google Scholar
• Levey AS, Coresh J. Chronic kidney disease. Lancet 2012;379(9811):165-80
   PubMed Web of Science ®Google Scholar
• System USRD. International Comparisons. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 2013
   Google Scholar
• Fioretto P, Mauer M. Histopathology of diabetic nephropathy. Semin Nephrol 2007;27(2):195-207
   PubMed Web of Science ®Google Scholar
• Fioretto P, Mauer M, Carraro A, et al. Renal structural changes in non-insulin-dependent diabetes mellitus. Am J Hypertens 1997;10(9 Pt 2):184S-8S
   PubMed Web of Science ®Google Scholar
• Fioretto P, Mauer M, Brocco E, et al. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 1996;39(12):1569-76
   PubMed Web of Science ®Google Scholar
• Raptis AE, Viberti G. Pathogenesis of diabetic nephropathy. Exp Clin Endocrinol Diabetes 2001;109(Suppl 2):S424-37
   PubMedGoogle Scholar
• Ohsawa M, Fujioka T, Ogasawara K, et al. High risks of all-cause and cardiovascular deaths in apparently healthy middle-aged people with preserved glomerular filtration rate and albuminuria: A prospective cohort study. Int J Cardiol 2013;170(2):167-72
   PubMed Web of Science ®Google Scholar
• Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet 2013;382(9888):260-72
   PubMed Web of Science ®Google Scholar
• Jha V, Wang AY, Wang H. The impact of CKD identification in large countries: the burden of illness. Nephrol Dial Transpl 2012;27(Suppl 3):iii32-8
   PubMedGoogle Scholar
• Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87(1):4-14
   PubMed Web of Science ®Google Scholar
• Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298(17):2038-47
   PubMed Web of Science ®Google Scholar
• Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab 2008;4(8):444-52
   PubMedGoogle Scholar
• Yamagishi S, Matsui T. Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid Med Cell Longev 2010;3(2):101-8
   PubMed Web of Science ®Google Scholar
• Mott JD, Khalifah RG, Nagase H, et al. Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility. Kidney Int 1997;52(5):1302-12
   PubMed Web of Science ®Google Scholar
• Silbiger S, Crowley S, Shan Z, et al. Nonenzymatic glycation of mesangial matrix and prolonged exposure of mesangial matrix to elevated glucose reduces collagen synthesis and proteoglycan charge. Kidney Int 1993;43(4):853-64
   PubMed Web of Science ®Google Scholar
• Yang CW, Vlassara H, Peten EP, et al. Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci USA 1994;91(20):9436-40
   PubMed Web of Science ®Google Scholar
• Vlassara H, Striker LJ, Teichberg S, et al. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 1994;91(24):11704-8
   PubMed Web of Science ®Google Scholar
• Yamagishi S, Takeuchi M, Makita Z. Advanced glycation end products and the pathogenesis of diabetic nephropathy. Contrib Nephrol 2001;134:30-5
   PubMed Web of Science ®Google Scholar
• Pedchenko VK, Chetyrkin SV, Chuang P, et al. Mechanism of perturbation of integrin-mediated cell-matrix interactions by reactive carbonyl compounds and its implication for pathogenesis of diabetic nephropathy. Diabetes 2005;54(10):2952-60
   PubMed Web of Science ®Google Scholar
• Cai W, He JC, Zhu L, et al. Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc Natl Acad Sci USA 2006;103(37):13801-6
   PubMed Web of Science ®Google Scholar
• Yamagishi S, Inagaki Y, Okamoto T, et al. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem 2002;277(23):20309-15
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Kato I, Doi T, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001;108(2):261-8
   PubMed Web of Science ®Google Scholar
• Wendt TM, Tanji N, Guo J, et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003;162(4):1123-37
   PubMed Web of Science ®Google Scholar
• Heizmann CW. The mechanism by which dietary AGEs are a risk to human health is via their interaction with RAGE: arguing against the motion. Mol Nutr Food Res 2007;51(9):1116-19
   PubMed Web of Science ®Google Scholar
• Yao D, Brownlee M. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 2010;59(1):249-55
   PubMed Web of Science ®Google Scholar
• Kanesaki Y, Suzuki D, Uehara G, et al. Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy. Am J Kidney Dis 2005;45(2):288-94
   PubMed Web of Science ®Google Scholar
• Tufro A, Veron D. VEGF and podocytes in diabetic nephropathy. Semin Nephrol 2012;32(4):385-93
   PubMed Web of Science ®Google Scholar
• Baelde HJ, Eikmans M, Lappin DW, et al. Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. Kidney Int 2007;71(7):637-45
   PubMed Web of Science ®Google Scholar
• Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, et al. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 2002;51(10):3090-4
   PubMed Web of Science ®Google Scholar
• de Vriese AS, Tilton RG, Elger M, et al. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001;12(5):993-1000
   PubMed Web of Science ®Google Scholar
• Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994;331(19):1286-92
   PubMed Web of Science ®Google Scholar
• Okuda S, Languino LR, Ruoslahti E, Border WA. Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix. J Clin Invest 1990;86(2):453-62
   PubMed Web of Science ®Google Scholar
• Sharma K, Ziyadeh FN. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 1995;44(10):1139-46
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Nakamura T, Noble NA, et al. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 1993;90(5):1814-18
   PubMed Web of Science ®Google Scholar
• Fukami K, Ueda S, Yamagishi S, et al. AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int 2004;66(6):2137-47
   PubMed Web of Science ®Google Scholar
• Zimanyi MA, Denton KM, Forbes JM, et al. A developmental nephron deficit in rats is associated with increased susceptibility to a secondary renal injury due to advanced glycation end-products. Diabetologia 2006;49(4):801-10
   PubMed Web of Science ®Google Scholar
• Tanimoto M, Gohda T, Kaneko S, et al. Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice. Metabolism 2007;56(2):160-7
   PubMed Web of Science ®Google Scholar
• Forbes JM, Thallas V, Thomas MC, et al. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J 2003;17(12):1762-4
   PubMedGoogle Scholar
• Tsuchida K, Makita Z, Yamagishi S, et al. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia 1999;42(5):579-88
   PubMed Web of Science ®Google Scholar
• Riser BL, Denichilo M, Cortes P, et al. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 2000;11(1):25-38
   PubMed Web of Science ®Google Scholar
• Roestenberg P, van Nieuwenhoven FA, Wieten L, et al. Connective tissue growth factor is increased in plasma of type 1 diabetic patients with nephropathy. Diabetes Care 2004;27(5):1164-70
   PubMed Web of Science ®Google Scholar
• Burns WC, Twigg SM, Forbes JM, et al. Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. J Am Soc Nephrol 2006;17(9):2484-94
   PubMed Web of Science ®Google Scholar
• Twigg SM, Cao Z, SV MC, et al. Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology 2002;143(12):4907-15
   PubMed Web of Science ®Google Scholar
• Ha H, Hwang IA, Park JH, Lee HB. Role of reactive oxygen species in the pathogenesis of diabetic nephropathy. Diabetes Res Clin Pract 2008;82(Suppl 1):S42-5
   PubMedGoogle Scholar
• Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329(20):1456-62
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345(12):851-60
   PubMed Web of Science ®Google Scholar
• Gilbert RE, Kim SA, Tuttle KR, et al. Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes. Diabetes Care 2007;30(4):995-6
   PubMed Web of Science ®Google Scholar
• Tuttle KR, Bakris GL, Toto RD, et al. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 2005;28(11):2686-90
   PubMed Web of Science ®Google Scholar
• Budhiraja S, Singh J. Protein kinase C beta inhibitors: a new therapeutic target for diabetic nephropathy and vascular complications. Fundam Clin Pharmacol 2008;22(3):231-40
   PubMed Web of Science ®Google Scholar
• Burgoyne JR, Mongue-Din H, Eaton P, Shah AM. Redox signaling in cardiac physiology and pathology. Circ Res 2012;111(8):1091-106
   PubMed Web of Science ®Google Scholar
• Dugan LL, You YH, Ali SS, et al. AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function. J Clin Invest 2013;123(11):4888-99
   PubMed Web of Science ®Google Scholar
• Chen JL, Francis J. Pyridoxamine, advanced glycation inhibition, and diabetic nephropathy. J Am Soc Nephrol 2012;23(1):6-8
   PubMed Web of Science ®Google Scholar
• Furukawa M, Gohda T, Tanimoto M, Tomino Y. Pathogenesis and novel treatment from the mouse model of type 2 diabetic nephropathy. ScientificWorldJournal 2013;2013:928197
   PubMed Web of Science ®Google Scholar
• Onuigbo M. Renoprotection and the Bardoxolone Methyl Story - Is This the Right Way Forward? A Novel View of Renoprotection in CKD Trials: a New classification scheme for renoprotective agents. Nephron Extra 2013;3(1):36-49
   Google Scholar
• Fried LF, Emanuele N, Zhang JH, et al. Combined Angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013;369(20):1892-903
   PubMed Web of Science ®Google Scholar
• Andersen S, Tarnow L, Rossing P, et al. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000;57(2):601-6
   PubMed Web of Science ®Google Scholar
• Liao J, Kobayashi M, Kanamuru Y, et al. Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice. J Nephrol 2003;16(6):841-9
   PubMed Web of Science ®Google Scholar
• Fan Q, Liao J, Kobayashi M, et al. Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. Nephrol Dial Transplant 2004;19(12):3012-20
   PubMed Web of Science ®Google Scholar
• Forbes JM, Cooper ME, Thallas V, et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 2002;51(11):3274-82
   PubMed Web of Science ®Google Scholar
• Yamagishi S, Takeuchi M, Inoue H. Olmesartan medoxomil, a newly developed angiotensin II type 1 receptor antagonist, protects against renal damage in advanced glycation end product (age)-injected rats. Drugs Exp Clin Res 2005;31(2):45-51
   PubMedGoogle Scholar
• Sebekova K, Gazdikova K, Syrova D, et al. Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products. J Hum Hypertens 2003;17(4):265-70
   PubMed Web of Science ®Google Scholar
• Saisho Y, Komiya N, Hirose H. Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: blood pressure-independent effect of valsartan. Diabetes Res Clin Pract 2006;74(2):201-3
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345(12):861-9
   PubMed Web of Science ®Google Scholar
• Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345(12):870-8
   PubMed Web of Science ®Google Scholar
• Ravid M, Savin H, Jutrin I, et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993;118(8):577-81
   PubMed Web of Science ®Google Scholar
• Moon JY, Tanimoto M, Gohda T, et al. Attenuating effect of angiotensin-(1-7) on angiotensin II-mediated NAD(P)H oxidase activation in type 2 diabetic nephropathy of KK-A(y)/Ta mice. Am J Physiol Renal Physiol 2011;300(6):F1271-82
   PubMed Web of Science ®Google Scholar
• Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367(23):2204-13
   PubMed Web of Science ®Google Scholar
• Onuigbo MA. Is renoprotection with RAAS blockade a failed paradigm? Have we learnt any lessons so far? Int J Clin Pract 2010;64(10):1341-6
   PubMed Web of Science ®Google Scholar
• Turgut F, Bolton WK. Potential new therapeutic agents for diabetic kidney disease. Am J Kidney Dis 2010;55(5):928-40
   PubMed Web of Science ®Google Scholar
• Khalifah RG, Baynes JW, Hudson BG. Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Commun 1999;257(2):251-8
   PubMed Web of Science ®Google Scholar
• Voziyan PA, Hudson BG. Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage. Cell Mol Life Sci 2005;62(15):1671-81
   PubMed Web of Science ®Google Scholar
• Onorato JM, Jenkins AJ, Thorpe SR, Baynes JW. Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine. J Biol Chem 2000;275(28):21177-84
   PubMed Web of Science ®Google Scholar
• Voziyan PA, Metz TO, Baynes JW, Hudson BG. A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. J Biol Chem 2002;277(5):3397-403
   PubMed Web of Science ®Google Scholar
• Degenhardt TP, Alderson NL, Arrington DD, et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002;61(3):939-50
   PubMed Web of Science ®Google Scholar
• Zheng F, Zeng YJ, Plati AR, et al. Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice. Kidney Int 2006;70(3):507-14
   PubMed Web of Science ®Google Scholar
• Williams ME, Bolton WK, Khalifah RG, et al. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol 2007;27(6):605-14
   PubMed Web of Science ®Google Scholar
• Bolton WK, Cattran DC, Williams ME, et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004;24(1):32-40
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Greene T, Spitalewiz S, et al. Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol 2012;23(1):131-6
   PubMed Web of Science ®Google Scholar
• Schwartz MM, Lewis EJ, Leonard-Martin T, et al. pathology patterns in type II diabetes mellitus: relationship with retinopathy. The Collaborative Study Group. Nephrol Dial Transplant 1998;13(10):2547-52
   PubMed Web of Science ®Google Scholar
• Pergola PE, Krauth M, Huff JW, et al. Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD. Am J Nephrol 2011;33(5):469-76
   PubMed Web of Science ®Google Scholar
• Pergola PE, Raskin P, Toto RD, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011;365(4):327-36
   PubMed Web of Science ®Google Scholar
• Li W, Khor TO, Xu C, et al. Activation of Nrf2-antioxidant signaling attenuates NFkappaB-inflammatory response and elicits apoptosis. Biochem Pharmacol 2008;76(11):1485-9
   PubMed Web of Science ®Google Scholar
• Dinkova-Kostova AT, Liby KT, Stephenson KK, et al. Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci USA 2005;102(12):4584-9
   PubMed Web of Science ®Google Scholar
• Levonen AL, Landar A, Ramachandran A, et al. Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products. Biochem J 2004;378(Pt 2):373-82
   PubMedGoogle Scholar
• Honda T, Rounds BV, Gribble GW, et al. Design and synthesis of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages. Bioorg Med Chem Lett 1998;8(19):2711-14
   PubMed Web of Science ®Google Scholar
• Ahmad R, Raina D, Meyer C, et al. Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179. J Biol Chem 2006;281(47):35764-9
   PubMed Web of Science ®Google Scholar
• Straus DS, Pascual G, Li M, et al. 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci USA 2000;97(9):4844-9
   PubMed Web of Science ®Google Scholar
• Kim HJ, Vaziri ND. Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol Renal Physiol 2010;298(3):F662-71
   PubMed Web of Science ®Google Scholar
• Ma Q, Battelli L, Hubbs AF. Multiorgan autoimmune inflammation, enhanced lymphoproliferation, and impaired homeostasis of reactive oxygen species in mice lacking the antioxidant-activated transcription factor Nrf2. Am J Pathol 2006;168(6):1960-74
   PubMed Web of Science ®Google Scholar
• Hong DS, Kurzrock R, Supko JG, et al. A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin Cancer Res 2012;18(12):3396-406
   PubMed Web of Science ®Google Scholar
• Saha PK, Reddy VT, Konopleva M, et al. The triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic-acid methyl ester has potent anti-diabetic effects in diet-induced diabetic mice and Lepr(db/db) mice. J Biol Chem 2010;285(52):40581-92
   PubMed Web of Science ®Google Scholar
• de Zeeuw D, Akizawa T, Audhya P, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 2013;369(26):2492-503
   PubMed Web of Science ®Google Scholar
• Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007;71(1):31-8
   PubMed Web of Science ®Google Scholar
• Zhang Z, Sun L, Wang Y, et al. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int 2008;73(2):163-71
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang Y, Ning G, et al. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci USA 2008;105(41):15896-901
   PubMed Web of Science ®Google Scholar
• Mizobuchi M, Morrissey J, Finch JL, et al. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol 2007;18(6):1796-806
   PubMed Web of Science ®Google Scholar
• Tan X, Li Y, Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 2006;17(12):3382-93
   PubMed Web of Science ®Google Scholar
• Li YC, Kong J, Wei M, et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002;110(2):229-38
   PubMed Web of Science ®Google Scholar
• Yuan W, Pan W, Kong J, et al. 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 2007;282(41):29821-30
   PubMed Web of Science ®Google Scholar
• de Borst MH, Vervloet MG, ter Wee PM, Navis G. Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am Soc Nephrol 2011;22(9):1603-9
   PubMed Web of Science ®Google Scholar
• Inoue K, Matsui I, Hamano T, et al. Maxacalcitol ameliorates tubulointerstitial fibrosis in obstructed kidneys by recruiting PPM1A/VDR complex to pSmad3. Lab Invest 2012;92(12):1686-97
   PubMed Web of Science ®Google Scholar
• de Borst MH, Hajhosseiny R, Tamez H, et al. Active vitamin D treatment for reduction of residual proteinuria: a systematic review. J Am Soc Nephrol 2013;24(11):1863-71
   PubMed Web of Science ®Google Scholar
• Masola V, Onisto M, Zaza G, et al. A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition. J Transl Med 2012;10:213
   PubMedGoogle Scholar
• Packham DK, Wolfe R, Reutens AT, et al. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol 2012;23(1):123-30
   PubMed Web of Science ®Google Scholar
• Hocher B, Schwarz A, Reinbacher D, et al. Effects of endothelin receptor antagonists on the progression of diabetic nephropathy. Nephron 2001;87(2):161-9
   PubMed Web of Science ®Google Scholar
• Andress DL, Coll B, Pritchett Y, et al. Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD). Life Sci 2012;91(13-14):739-42
   PubMed Web of Science ®Google Scholar
• Mann JF, Green D, Jamerson K, et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010;21(3):527-35
   PubMed Web of Science ®Google Scholar
• McClellan WM, Plantinga LC. A public health perspective on CKD and obesity. Nephrol Dial Transplant 2013;28(Suppl 4):iv37-42
   PubMedGoogle Scholar
• Boor P, Celec P, Behuliak M, et al. Regular moderate exercise reduces advanced glycation and ameliorates early diabetic nephropathy in obese Zucker rats. Metabolism 2009;58(11):1669-77
   PubMed Web of Science ®Google Scholar
• Ishikawa Y, Gohda T, Tanimoto M, et al. Effect of exercise on kidney function, oxidative stress, and inflammation in type 2 diabetic KK-A(y) mice. Exp Diabetes Res 2012;2012:702948
   PubMedGoogle Scholar
• Palmer-Smith S, Rosser LG, Tull J, et al. X-linked lissencephaly with ambiguous genitalia - a case presentation. J Med Genet 2011;48:S58-8
   Web of Science ®Google Scholar